A 90-day digital intervention significantly improved blood glucose control and reduced weight among adults with type 2 diabetes, highlighting the potential of continuous tech support alongside medication.
A study published in Frontiers in Endocrinology reports that a digitally delivered diabetes programme produced significant short-term improvements in blood sugar control and weight among adults with type 2 diabetes. According to the paper, participants in the 90-day intervention saw meaningful reductions in HbA1c, a measure of average blood glucose over about three months, alongside better fasting blood sugar, lower body weight, reduced body mass index, smaller waist circumference and less diabetes-related distress.
The findings add to a growing body of research suggesting that continuous digital support can improve outcomes in type 2 diabetes, particularly when patients receive regular monitoring and personalised guidance rather than relying only on periodic clinic visits. Frontiers has also published a separate 2024 study on a hybrid care model that found better HbA1c results, as well as improvements in lipid levels, kidney function and cardiovascular risk markers, when ongoing data tracking was combined with tailored support.
The Sugarfit report says the strongest results were seen among participants who stuck most closely to the programme, with higher adherence linked to a larger HbA1c drop of 1.7%. Shivtosh Kumar, Sugarfit’s co-founder and chief product officer, said in a statement that the results show what can happen “when technology enables structured, continuous support at scale”, arguing that digital tools can help fill the gap between infrequent doctor visits.
The new paper lands alongside broader evidence on GLP-1 receptor agonists, a class of diabetes drugs that has become central to treatment discussions because of its blood sugar and weight effects. Recent Frontiers studies on real-world use of these medicines have reported average HbA1c reductions of about 0.9%, with semaglutide also associated with lower fasting glucose and weight over time, underscoring how digital care programmes and medication-based approaches are both shaping modern diabetes management.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
